Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 History  





2 Decision-making process  





3 Notable guidelines  





4 See also  





5 References  





6 External links  














Federal Joint Committee (Germany)






Deutsch
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Logo

The Federal Joint Committee (German: Gemeinsamer Bundesausschuss) refers to a group of German public health agencies that were merged in 2004, under an independent chairman.[1] It is authorized to make binding regulations growing out of health reform bills passed by lawmakers, along with routine decisions regarding healthcare in Germany.[1]

Although the committee is not a subordinate agency and is independent of the Ministry of Health, government officials are responsible for exercising legal supervision over the committee's decisions and guidelines. As a supreme decision-making body, the Committee exerts a direct influence on the healthcare provisions for millions of people.[2]

History[edit]

The Federal Joint Committee (G-BA) was formed in 2004 by the merger of the following organizations

These organizations had been created several decades ago[when?] to ensure supervision of the professional relationship between doctors and health insurers. Their roots can be partially traced back to the Weimar Republic in the late-1910s and 1920s.[3] In 2004, they were renamed and merged into the Federal Joint Committee (G-BA) as follows:

As a supreme decision-making body, the Joint Committee exerts a direct influence on the healthcare provisions for millions of people.[2]

Decision-making process[edit]

In the early stages of the Committee 's decision-making process, assessment reports of diagnostic or therapeutic interventions are prepared by the Institute for Quality and Efficiency in Health Care on behalf of the committee.[5] All resolutions and guidelines passed by the Federal Joint Committee are subsequently audited by the Ministry of Health.[4]

The directives issued by the committee are legally binding for publicly insured persons as well as for the providers and payers of health care. In total, healthcare provisions for 70 million people, excluding those who are privately insured, are determined by the committee.[2]

Notable guidelines[edit]

Following the German acupuncture trials from 2002 to 2006, the Committee decided to include acupuncture into the catalogue of services covered by statutory health insurance organizations for the treatment of low back pain and knee pain.[6]

On June 17, 2010, the Committee removed the usage of glinides from general prescription guidelines for the reduction of human glucose levels. It justified its decision by referring to the conclusion of the Institute for Quality and Efficiency in Health Care that proof of efficacy was lacking.[7]

In 2013, the Committee issued a preliminary decision ruling that a fixed dose combinationofStribild does not offer a benefit over Atripla for HIV treatment.[8]

See also[edit]

References[edit]

  1. ^ a b E. REINHARDT, UWE (2009-07-24). "A German Import That Could Help U.S. Health Reform". The New York Times. Retrieved 25 May 2013. Germany's joint committee was established in 2004 and authorized to make binding regulations growing out of health reform bills passed by lawmakers, along with routine coverage decisions. The ministry of health reserves the right to review the regulations for final approval or modification. The joint committee has a permanent staff and an independent chairman.
  • ^ a b c Fricke, Frank-Ulrich; Dauben, Hans Peter (June 2009). "Health Technology Assessment: A Perspective from Germany". Value in Health. 12: S20–S27. doi:10.1111/j.1524-4733.2009.00555.x. PMID 19523181. The G-BA is the supreme decision-making body of the so-called self-governing system in Germany. Physicians, dentists, hospitals, sickness funds, and patients are represented in the G-BA. The G-BA issues directives and, thus, determines the benefit package of the SHI covering about 70 million people. Finally, the G-BA is responsible for reimbursement decisions.
  • ^ a b c d e Kälble, Bernhard Borgetto ; Karl (2007). Medizinsoziologie : sozialer Wandel, Krankheit, Gesundheit und das Gesundheitssystem (in German). Weinheim: Juventa-Verl. p. 184. ISBN 9783779914846.{{cite book}}: CS1 maint: multiple names: authors list (link)
  • ^ a b c d "The Federal Joint Committee: Who we are and what we do". Gemeinsamer Bundesausschuss. Retrieved 25 May 2013.
  • ^ Wieseler, B.; McGauran, N.; Kaiser, T. (12 October 2010). "Finding studies on reboxetine: a tale of hide and seek". BMJ. 341: c4942. doi:10.1136/bmj.c4942. PMID 20940211. Produces health technology assessments on diagnostic or therapeutic interventions and health economic evaluations for the Federal Joint Committee (G-BA)—the statutory health insurance system's main decision making body
  • ^ Karin Hertzer (August 12, 2009). "Akupunktur ist wirksam". Focus (German magazine) (in German). Der Gemeinsame Bundesausschuss der Ärzte und Krankenkassen entschied dann im April 2006, die Akupunktur als Kassenleistung gegen Rücken- und Knieschmerzen anzuerkennen.
  • ^ Kreis, J; Busse, R (January 2012). "From evidence assessments to coverage decisions?: the case example of glinides in Germany". Health Policy (Amsterdam, Netherlands). 104 (1): 27–31. doi:10.1016/j.healthpol.2011.11.006. PMID 22136812.
  • ^ Ed Silverma (2013-09-18). "Will German Regulators Dampen Gilead Hopes For Its Stribild AIDS Drug?". Forbes. Retrieved 20 November 2013.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Federal_Joint_Committee_(Germany)&oldid=1214455444"

    Category: 
    Medical and health organisations based in Berlin
    Hidden categories: 
    CS1 maint: multiple names: authors list
    CS1 German-language sources (de)
    All articles with vague or ambiguous time
    Vague or ambiguous time from March 2020
    Articles with ISNI identifiers
    Articles with VIAF identifiers
    Articles with GND identifiers
     



    This page was last edited on 19 March 2024, at 01:49 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki